Randal Henderson, M.D., M.B.A. – An Expert Talks About Prostate Cancer and Proton Therapy

Bringing awareness to prostate cancer is the first step in early detection and effective treatment. Randal Henderson, M.D., M.B.A., associate medical director of the UF Health Proton Therapy Institute and a professor of radiation oncology at the UF College of Medicine, is an expert in prostate cancer treatment. He was recently interviewed about the benefits of proton therapy in treating the disease. Dr. Henderson discusses the excellent patient outcomes reported in published studies and the new national clinical trial being led by the Institute that will compare the outcomes of patients treated with proton therapy or conventional radiation therapy. Watch this video to learn more.


Physicians and Physicist Added to Expert Proton Therapy Staff

The UF Health Proton Therapy Institute welcomes two physicians and a physicist to its medical team.


Adam L. Holtzman, M.D.

Adam L. Holtzman, M.D.Dr. Holtzman is an assistant professor in the Department of Radiation Oncology at the University of Florida College of Medicine. While skilled in all external beam radiation modalities, he specializes in proton therapy for skull-based and central nervous system malignancies. He received his undergraduate, medical, and residency training from the University of Florida. An established researcher, his work has been published in multiple peer-reviewed medical journals and presented at international conferences. Dr. Holtzman has received multiple awards in recognition for his dedication to clinical care, compassion and research. He was honored as Best of American Society for Radiation Oncology 57th Annual Meeting, inducted into the Gold Humanism Honors Society, and received the Outstanding Resident Educator Award.


Raymond B. Mailhot, M.D., M.P.H.

Raymond B. Mailhot, M.D., M.P.H.Dr. Mailhot is an assistant professor in the Department of Radiation Oncology at the University of Florida College of Medicine. His areas of treatment and research include proton therapy for pediatric cancer and breast cancer. He completed his undergraduate and medical training at Washington University in St. Louis and post graduate training at Harvard University and New York University, where he served as chief resident. He has published multiple research articles in peer-reviewed medical journals and presented research at international medical conferences. His academic and professional honors include the J. Max Rukes Full Tuition Merit Scholarship, Washington University School of Medicine; Merit Scholarship, Harvard School of Public Health; Jonathan Mann Foreign Rotation Fellowship Award; and American Society of Clinical Oncology Conquer Cancer Fellowship Award. He serves on committee for the American Society for Radiation Oncology.


Mark Artz, Ph.D.

Mark Artz, Ph.D.Dr. Artz is an assistant professor in the Department of Radiation Oncology at the University of Florida College of Medicine. He received his bachelor’s and master’s degrees from the Massachusetts Institute of Technology, where he contributed to the development of superconducting cyclotrons and gantries for proton therapy. Most recently, as an adjunct professor at the University of Tennessee and medical physicist fellow at the Provision Proton Therapy Center, Knoxville, Dr. Artz was responsible for clinical commissioning and operation of IBA and ProNova Proton and Eleckta Photon, including treatment planning, quality assurance and clinical development. He also developed a CAMPEP Master of Science degree program in Medical Physics with the University of Tennessee College of Engineering.


Cruise Organized by Proton Alum

Next April, proton alumni are setting sail aboard a cruise liner in the Mediterranean, and you’re invited. Organized by Rose and George Rollins (alum 2018), it is meant as an informal reunion for proton alumni. According to the Rollinses, it’s a chance to celebrate successful treatment, relax and share how the UF Health Proton Therapy Institute has impacted proton graduates’ lives post treatment.

“This cruise is a personal endeavor by three couples who bonded in treatment at the Proton Center and who want to continue that relationship,” said the Rollinses. “We also want to include other graduates who might be interested in this celebration cruise.”

The ship is Holland America’s Koningsdam, christened in 2016. Originating in Civitavecchia (Rome), Italy, the nine-day, six-port Mediterranean cruise will visit Croatia, Greece and Italy.

The Rollinses are retired airline employees and have contacted Holland America’s Group Administration Department directly to set up the proton alumni group.

For more information, contact George and Rose Rollins at 678-907-9339 or geonrose@bellsouth.net.


Executive Director Message


StuartKlein.pngAs leaders in radiation oncology, the University of Florida had the vision to bring proton therapy to the region. Our medical director Nancy P. Mendenhall, M.D., was the radiation oncology department chair at the time and proton therapy was her answer to the big question: what can we do to improve patient care? In radiation oncology, improvement means giving the most radiation possible to achieve a cure while reducing, or eliminating, the amount of collateral damage to healthy tissue. With this goal in mind, our facility was developed as a regional resource for patient care and research. We stand as one of the most successful proton therapy centers in operation – one that emphasizes excellence in patient care and in academic medicine to bring about improvements in patient outcomes.


Stuart L. Klein

Executive Director

Celebrating 12 Years of Proton Therapy Excellence

Celebrating 12 years of Proton Therapy Excellence

The UF Health Proton Therapy Institute treated its first patient on August 14, 2006, becoming the fifth proton therapy center in the U.S. and the first in the Southeast. Established as an academic clinical treatment and research center, the Institute during its first 12 years has rapidly made a significant impact on patient care and proton therapy techniques used to treat cancer.

Pediatric patients have been a major focus since day one. It is now widely recognized that proton therapy is the standard of care for children needing radiation treatment for cancer. Because proton therapy is targeted, less radiation is given to the healthy tissues of children who are still growing and are more susceptible to side effects of radiation. The Institute has the largest pediatric proton therapy program in the world, treating about 25 to 30 children each day.

As a regional resource, the Institute has treated more than 7,700 patients since opening, including 1,600 children. Patients have come from the Jacksonville area, all 50 states and 32 countries for the advanced radiation treatment delivered by the renowned team of cancer experts at the University of Florida.

The Institute is active in clinical research, and 98 percent of patients participate in outcomes studies. This rigorous follow-up has resulted in more than 133 articles published in peer-reviewed medical journals. The evidence points to an important role for proton therapy in treating cancer and confirms it is effective, safe and reduces side effects for many types of cancer.

This year, the Institute is heading up a national, large-scale prostate cancer clinical trial that will compare proton therapy and standard radiation patient outcomes. Later this fall, the facility expansion project will reach a major milestone when the new cyclotron arrives. This addition, when complete, will mean more access to proton therapy for patients across the region for years to come.

Expertise in Proton Therapy – R. Charles Nichols, M.D.

One of our expert physicians is R. Charles Nichols, M.D., radiation oncologist and UF Department of Radiation Oncology associate professor. He was interviewed recently about proton therapy, the benefits of proton therapy for prostate cancer patients, and more. He describes clinical research outcomes and how the treatment experience at UF Health Proton Therapy Institute is an international model for patient care. To learn more, watch the video below.


UF Breaks Record For Research Awards

UF Breaks Record For Research Awards

The University of Florida received a record $837.6 million in research funding in fiscal year 2018, surpassing the previous record set in fiscal 2016 by nearly 16 percent. Federal government funds accounted for the majority of the increase with additional funding coming from foundations, non-profits, industry and the State of Florida.

Notably, the College of Medicine is the largest recipient of research funding bringing in 42 percent of UF’s total. The UF Health Proton Therapy Institute was among the research programs that received significant new funding in fiscal year 2018. Under the leadership of Medical Director Nancy P. Mendenhall, M.D., the Institute was awarded $11.9 million by the Patient-Centered Outcomes Research Institute for a large-scale clinical study on prostate cancer comparing the effectiveness of proton therapy and standard radiation. The project will compare 1,500 patients treated with proton therapy and 1,500 patients treated with standard radiation therapy at 42 treatment centers across the U.S.

“These record-shattering numbers reflect the growing prestige and reputation of the University of Florida as a research powerhouse,” said David Norton, UF’s vice president for research. “Each award represents targeted funding for UF faculty to advance the boundaries of discovery and knowledge in fields ranging from health care to engineering to understanding the fundamental nature of our universe. The record amount of total funding is also testament to the significant investment the state has made in UF over the past decade, which has enabled us to attract, retain and support outstanding research faculty across the institution.”

Play Golf. Fight Cancer.® Classic Opens Registration

Steve Spurrier
Steve Spurrier,
Honorary Chairman
University of Florida Ambassador

The 14th Annual Play Golf. Fight Cancer.® Classic is registering players and seeking sponsors for the October 8 event. The tournament is being held at the renowned Slammer & Squire golf course at the World Golf Village, St. Augustine, Fla. Honorary Chair Steve Spurrier, Gator Great and one of four people elected to the College Football Hall of Fame as a player and as a coach, invites you to join him in supporting UF Health Proton Therapy Institute’s clinical research program.

“As honorary chair of this year’s tournament, I’m proud of the UF Health Proton Therapy Institute and the work they have been doing to provide the best possible treatment for cancer patients and to define, through research, the best roles and methods of proton therapy,” said Spurrier.

The Institute currently has 21 active clinical studies. Importantly, approximately 98 percent of patients participate in a registry study to track outcomes following treatment and 31 percent of patients are enrolled in clinical trials, while the national average of clinical trial participation is 3 percent. Your support ensures the continued growth of the clinical research program, gathering data that is necessary to advance the understanding of proton therapy.

“Our primary missions at UF Health Proton Therapy Institute are clinical care and clinical research,” said Nancy P. Mendenhall, M.D., medical director. “Our purpose is to give patients the best quality cancer treatment. We invest heavily in research because we want to see a day when all patients with cancer are cured and none are burdened with side effects of treatment.”

To participate and for more information, visit www.playgolffightcancer.org.


Executive Director Message


StuartKlein.pngProton therapy continues to expand in the U.S. Back in 2006 when we opened, we were the fifth facility to operate in the U.S. Today there are now 27 proton facilities scattered across the country with even more being considered. What makes us different? In short, I believe it’s our people. We have approximately 220 employees that work in our center. Each represents the best and the brightest with an unquestioning dedication to provide our patients with the best care possible. This is engrained in our DNA. We constantly work hard to achieve this goal, and are grateful for the opportunity to serve our patients on their journey in beating cancer. We’re always open to suggestions on how to improve our service. Please let us know if there’s anything you feel we could do to improve.


Stuart L. Klein

Executive Director

Sarcoma Awareness


July is Sarcoma Awareness Month and Michael Rutenberg, MD, PhD, UF Health Proton Therapy Institute radiation oncologist and UF Department of Radiation Oncology assistant professor, was interviewed on First Coast Living about this rare cancer of the soft tissue and proton therapy’s role in treatment of the malignancy. As with other cancers treated with proton therapy, sarcoma patients can benefit from the targeted dose and reduced side effects. To learn more, watch the video below.



About This Newsletter

The Precision Newsletter is an electronic-only publication that is distributed by email. Each issue is sent monthly to patients, alumni patients and friends of the University of Florida Health Proton Therapy Institute. As the official newsletter of the Institute, the content is compiled and prepared by our communications representative and approved by the editor Stuart Klein, executive director of UF Health Proton Therapy Institute. Special bulletin newsletters may occasionally be prepared when timely topics and new developments in proton therapy occur. If you would like to send a Letter to the Editor, please click here.


Keep In Touch

It is easy to stay in touch with us online at floridaproton.org . Look at the top right corner of the homepage for Facebook , Twitter and YouTube icons, click and join us in the social media conversation. Also on the right side of the homepage there is a button for VTOC Patient Portal . Click here to open your secure account, view your records, complete clinical trial questionnaires and communicate with your nurse case manager.


Knowing how you are feeling during and after treatment is essential to providing you the best care possible and contributes to the care of future patients.